---
schema_version: "secwatch.filing_event.v1"
accession: "0001022079-23-000006"
form_type: "8-K"
ticker: "DGX"
cik: "0001022079"
company_name: "QUEST DIAGNOSTICS INC"
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T01:41:06.763526+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Quest Diagnostics Q4 revenue down 15% to $2.33B; base business up 6.3%; raises dividend 7.6%

## Summary
- Q4 reported net revenues $2.33B (-15% YoY); base business revs $2.15B (+6.3%); COVID revs $184M (-74.6%).
- Q4 reported diluted EPS $0.87 (down 72.1%); adjusted diluted EPS $1.98 (down 40.5%).
- Full year 2022 net revenues $9.88B (-8.4%); base business revs $8.43B (+5.1%); COVID revs $1.45B (-47.5%).
- FY2023 guidance: net revs $8.83-9.03B; base business up 2.6-3.8%; adjusted EPS $8.40-$9.00.
- Board increased quarterly dividend 7.6% to $0.71 (payable Apr 24) and authorized additional $1B share repurchase.

## SEC filing metadata
- accession: 0001022079-23-000006
- form_type: 8-K
- ticker: DGX
- cik: 0001022079
- company_name: QUEST DIAGNOSTICS INC
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000006/0001022079-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000006/dgx-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001022079-23-000006
- JSON: https://secwatch.observer/filing/0001022079-23-000006.json
- Plain text: https://secwatch.observer/filing/0001022079-23-000006.txt

## Key facts
- Earnings Releases
  QUEST DIAGNOSTICS INC reported Full year 2023 results: revenue $8.83 billion $9.03 billion, EPS $7.61 $8.21. Guidance initiated.
  - Period: Full year 2023
  - Revenue: $8.83 billion $9.03 billion
  - EPS: $7.61 $8.21
  - Guidance: initiated
  - Result: guidance update
  source text: We estimate full year 2023 guidance as follows: Low High Net revenues $8.83 billion $9.03 billion Net revenues decrease (10.7)% (8.6)% Base business revenues (a) $8.65 billion $8.75 billion Base business revenues increase 2.6% 3.8% COVID-19 testing revenues $175 million $275 million COVID-19 testing revenues decrease (88.0)% (81.1)% Reported diluted EPS $7.61 $8.21 Adjusted diluted EPS $8.40 $9.00 Cash provided by operations At least $1.3 billion Capital expenditures Approximately $400 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000006/0001022079-23-000006-index.htm
- Earnings Releases
  QUEST DIAGNOSTICS INC reported Three Months Ended December 31, 2022 results: revenue $2.33 billion, net income $101 million, EPS $0.87.
  - Period: Three Months Ended December 31, 2022
  - Revenue: $2.33 billion
  - Net income: $101 million
  - EPS: $0.87
  - Result: reported results
  source text: Fourth quarter revenues of $2.33 billion, down 15.0% from 2021 • Fourth quarter reported diluted earnings per share ("EPS") of $0.87, down 72.1% from 2021; and adjusted diluted EPS of $1.98, down 40.5% from 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000006/0001022079-23-000006-index.htm
- Earnings Releases
  QUEST DIAGNOSTICS INC reported Full year ended December 31, 2022 results: revenue $9.88 billion, net income $946 million, EPS $7.97.
  - Period: Full year ended December 31, 2022
  - Revenue: $9.88 billion
  - Net income: $946 million
  - EPS: $7.97
  - Result: reported results
  source text: Full year revenues of $9.88 billion, down 8.4% from 2021 • Full year reported diluted EPS of $7.97, down 48.7% from 2021; and adjusted diluted EPS of $9.95, down 30.1% from 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000006/0001022079-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.